Inhibition of mammalian deoxyribonucleic acid synthesis by neocarzinostatin: selective effect on replicon initiation in CHO cells and resistant synthesis in ataxia telangiectasia fibroblasts.
Inhibition of mammalian deoxyribonucleic acid synthesis by neocarzinostatin: selective effect on replicon initiation in CHO cells and resistant synthesis in ataxia telangiectasia fibroblasts.
复制标题
新制癌菌素对哺乳动物脱氧核糖核酸合成的抑制：对 CHO 细胞中复制子起始的选择性作用和共济失调毛细血管扩张成纤维细胞中的抗性合成。
DOI：
10.1021/bi00266a020
复制
发表时间：
1982
期刊：
影响因子：
2.9
通讯作者：
Goldberg,IH
中科院分区：
文献类型：
--
作者：
Povirk,LF;Goldberg,IH
材料与方法。临床NCS浓度为0.5 mg/mL (A273= 1.4)，临床博来霉素（Blenoxane）由Dr. WT Bradner of Bristol Laboratories提供。由H. Ume-zawa教授从Sidney Farber癌症研究所的T. S. A. Sarny博士处获得的auromomycin，将其溶解在蒸馏水中，用分光光度法测定其浓度，假设E\\ = 9.0 f。1982年5月17日收到。这项工作得到了美国公共卫生服务研究基金GM 12573和国立卫生研究院奖学金CA 06475 （LFP）的支持。
Materials and Methods Drugs. Clinical NCS with a concentration of 0.5 mg/mL (A273= 1.4) and clinical bleomycin (Blenoxane) were obtained from Dr. WT Bradner of Bristol Laboratories. Auro-momycin, obtained from Dr. T. S. A. Sarny of Sidney Farber Cancer Institute through the courtesy of Professor H. Ume-zawa, was dissolved in distilled water and its concentration determined spectrophotometrically assuming an E\\of 9.0 f From the Department of Pharmacology, Harvard Medical School, Boston, Massachusetts 02115. Received May 17, 1982. This work was supported by US Public Health Service Research Grant GM 12573 and Fellowship CA 06475 (LFP) from the National Institutes of Health.